Jim Simons’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-110,560
| Closed | -$24.4M | – | 3297 |
|
|
2025
Q4 | $24.4M | Buy |
110,560
+6,300
| +6% | +$1.02M | 0.04% | 521 |
|
|
2025
Q3 | $9.98M | Sell |
104,260
-52,517
| -33% | -$3.35M | 0.01% | 1093 |
|
|
2025
Q2 | $7.64M | Buy |
156,777
+64,260
| +69% | +$1.54M | 0.01% | 1250 |
|
|
2025
Q1 | $1.99M | Sell |
92,517
-3,100
| -3% | -$68.9K | ﹤0.01% | 2009 |
|
|
2024
Q4 | $2.57M | Sell |
95,617
-2,200
| -2% | -$35.7K | ﹤0.01% | 1884 |
|
|
2024
Q3 | $1.05M | Buy |
97,817
+2,300
| +2% | +$27.6K | ﹤0.01% | 2421 |
|
|
2024
Q2 | $1.14M | Sell |
95,517
-32,232
| -25% | -$441K | ﹤0.01% | 2250 |
|
|
2024
Q1 | $2.35M | Buy |
127,749
+37,640
| +42% | +$540K | ﹤0.01% | 1928 |
|
|
2023
Q4 | $1.43M | Buy |
90,109
+10,125
| +13% | +$163K | ﹤0.01% | 2171 |
|
|
2023
Q3 | $1.51M | Buy |
79,984
+2,505
| +3% | +$49.2K | ﹤0.01% | 2036 |
|
|
2023
Q2 | $1.75M | Buy |
77,479
+14,640
| +23% | +$344K | ﹤0.01% | 2085 |
|
|
2023
Q1 | $1.6M | Buy |
62,839
+3,570
| +6% | +$101K | ﹤0.01% | 2161 |
|
|
2022
Q4 | $896K | Sell |
59,269
-5,395
| -8% | -$64.4K | ﹤0.01% | 2596 |
|
|
2022
Q3 | $812K | Buy |
64,664
+6,851
| +12% | +$94.6K | ﹤0.01% | 2624 |
|
|
2022
Q2 | $565K | Sell |
57,813
-14,079
| -20% | -$174K | ﹤0.01% | 3089 |
|
|
2022
Q1 | $1.2M | Buy |
71,892
+1,179
| +2% | +$20K | ﹤0.01% | 2610 |
|
|
2021
Q4 | $1.8M | Buy |
70,713
+14,700
| +26% | +$458K | ﹤0.01% | 2228 |
|
|
2021
Q3 | $2.51M | Buy |
56,013
+3,698
| +7% | +$140K | ﹤0.01% | 1920 |
|
|
2021
Q2 | $2.11M | Buy |
52,315
+11,890
| +29% | +$503K | ﹤0.01% | 2221 |
|
|
2021
Q1 | $2.15M | Sell |
40,425
-37,558
| -48% | -$1.85M | ﹤0.01% | 2178 |
|
|
2020
Q4 | $3.12M | Buy |
77,983
+15,248
| +24% | +$758K | ﹤0.01% | 1870 |
|
|
2020
Q3 | $3.58M | Buy |
62,735
+5,258
| +9% | +$371K | ﹤0.01% | 1767 |
|
|
2020
Q2 | $4.24M | Buy |
57,477
+10,697
| +23% | +$693K | ﹤0.01% | 1745 |
|
|
2020
Q1 | $2.32M | Buy |
46,780
+6,997
| +18% | +$419K | ﹤0.01% | 1977 |
|
|
2019
Q4 | $3.06M | Buy |
39,783
+5,999
| +18% | +$275K | ﹤0.01% | 2118 |
|
|
2019
Q3 | $1.35M | Buy |
33,784
+3,247
| +11% | +$109K | ﹤0.01% | 2468 |
|
|
2019
Q2 | $1.03M | Buy |
30,537
+10,700
| +54% | +$445K | ﹤0.01% | 2667 |
|
|
2019
Q1 | $1.05M | Buy |
19,837
+4,012
| +25% | +$220K | ﹤0.01% | 2648 |
|
|
2018
Q4 | $744K | Buy |
15,825
+340
| +2% | +$24.3K | ﹤0.01% | 2713 |
|
|
2018
Q3 | $1.36M | Buy |
15,485
+1,220
| +9% | +$108K | ﹤0.01% | 2470 |
|
|
2018
Q2 | $1.48M | Buy |
14,265
+1,180
| +9% | +$111K | ﹤0.01% | 2425 |
|
|
2018
Q1 | $1.05M | Buy |
13,085
+4,120
| +46% | +$563K | ﹤0.01% | 2645 |
|
|
2017
Q4 | $1.22M | Buy |
8,965
+1,860
| +26% | +$282K | ﹤0.01% | 2590 |
|
|
2017
Q3 | $1.15M | Buy |
7,105
+330
| +5% | +$46.9K | ﹤0.01% | 2525 |
|
|
2017
Q2 | $1.02M | Buy |
6,775
+5,000
| +282% | +$691K | ﹤0.01% | 2553 |
|
|
2017
Q1 | $277K | Sell |
1,775
-720
| -29% | -$126K | ﹤0.01% | 2930 |
|
|
2016
Q4 | $519K | Buy |
2,495
+320
| +15% | +$66.5K | ﹤0.01% | 2748 |
|
|
2016
Q3 | $498K | Buy |
2,175
+835
| +62% | +$193K | ﹤0.01% | 2816 |
|
|
2016
Q2 | $276K | Buy |
+1,340
| New | +$324K | ﹤0.01% | 2967 |
|
Jim Simons's CDTX Position: Q1 2026 in Review
Jim Simons sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 110,560 shares — an estimated $24.4M sold.
Jim Simons first reported a position in CDTX in Q2 2016 and held it in 39 quarters. The position peaked at $24.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Jim Simons reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Jim Simons sold 110,560 Cidara Therapeutics shares in Q1 2026, an estimated $24.4M.
- Jim Simons first reported a position in Cidara Therapeutics in Q2 2016 and held it in 39 quarters.
- Jim Simons's Cidara Therapeutics position peaked at $24.4M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.